Overview

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have advanced or metastatic soft tissue sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Collaborator:
National Cancer Institute (NCI)
Treatments:
Soblidotin